Viking Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VKTX research report →
Companywww.vikingtherapeutics.com
Viking Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
- CEO
- Brian Lian
- IPO
- 2015
- Employees
- 45
- HQ
- San Diego, CA, US
Price Chart
Valuation
- Market Cap
- $3.42B
- P/E
- -7.20
- P/S
- 0.00
- P/B
- 6.78
- EV/EBITDA
- -6.58
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -71.31%
- ROIC
- -100.02%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-359,639,000 · -227.05%
- EPS
- $-3.19 · -215.84%
- Op Income
- $-393,342,000
- FCF YoY
- -217.45%
Performance & Tape
- 52W High
- $43.15
- 52W Low
- $22.96
- 50D MA
- $33.08
- 200D MA
- $32.65
- Beta
- 0.71
- Avg Volume
- 2.38M
Get TickerSpark's AI analysis on VKTX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 10, 26 | Aubuchon Neil William | buy | 4,475 |
| Jan 12, 26 | Aubuchon Neil William | other | 180,000 |
| Jan 12, 26 | Aubuchon Neil William | other | 0 |
| Jan 2, 26 | ZANTE GREG | other | 32,049 |
| Jan 5, 26 | ZANTE GREG | sell | 31,961 |
| Jan 2, 26 | ZANTE GREG | other | 41,000 |
| Jan 5, 26 | ZANTE GREG | sell | 13,900 |
| Jan 5, 26 | ZANTE GREG | sell | 10,300 |
| Jan 5, 26 | ZANTE GREG | sell | 1,500 |
| Jan 2, 26 | ZANTE GREG | other | 91,000 |
Our VKTX Coverage
We haven't published any research on VKTX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate VKTX Report →